



Pamela Vig, PhD Joins Presidio Pharmaceuticals, Inc. as Senior Director of Clinical Research

San Francisco, CA – June 2, 2010 - Presidio Pharmaceuticals, Inc. is pleased to announce that Pamela Vig, Ph.D. has joined the company as Senior Director of Clinical Research.

“Pam’s extensive background in antiviral drug development is an important boost to our clinical development programs,” said Nathaniel Brown, M.D., Chief Medical Officer. “As we enter into a series of clinical trials for our lead hepatitis C virus (HCV) NS5A inhibitor, PPI-461, Pam’s expertise will be of great value to optimizing the design and conduct of our clinical trial programs. We are very pleased to have Pam join us to further build Presidio’s drug development capacity.”

Pam brings more than sixteen years of experience in clinical drug development and program management. She previously served as Director, Global Medical Affairs, at Johnson & Johnson Pharmaceutical Services in London, UK, where she was responsible for the strategy and optimization of late-stage development and commercialization of telaprevir for HCV and etravirine for HIV. Pam also served as the Director of Clinical Development in Europe for Viropharma, and as Associate Director for Medical Affairs in Europe for Idenix Pharmaceuticals. Previously, Pam served in clinical development positions with Gilead Sciences, Coulter Pharmaceuticals and Chiron Corporation in the US.

Pam earned her B.S. degree in Biology at University of Nevada, Reno, and her M.Phil and Ph.D. degrees from Imperial College London, in the Departments of Hepatology and Pathology.

“I’m delighted to join Presidio Pharmaceuticals at this pivotal stage of its growth,” said Dr. Vig. “I look forward to managing the clinical programs as Presidio advances PPI-461 in the hope of developing a broadly-active, direct-acting therapeutic agent for patients with hepatitis C.”

ABOUT PRESIDIO

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV-1 and HCV. For more information, please visit our website at www.presidiopharma.com.

Contact: Omar K. Haffar, PhD
415-655-7561
omar@presidiopharma.com